Laniquidar

• CAT Number: I007616
• CAS Number: 197509-46-9
• Molecular Formula: C37H36N4O3
• Molecular Weight: 584.72
• Purity: ≥95%
• Synonyms: Laniquidar; R101933; R 101933; R-101933.;methyl 11-(1-(4-(quinolin-2-ylmethoxy)phenethyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepine-3-carboxylate
• Target: P-glycoprotein
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term , or -20°C for long term.
• IUPAC Name: methyl 11-[1-[2-[4-(quinolin-2-ylmethoxy)phenyl]ethyl]piperidin-4-ylidene]-5,6-dihydroimidazo[2,1-b][3]benzazepine-3-carboxylate
• InChI: InChI=1S/C37H36N4O3/c1-43-37(42)34-24-38-36-35(32-8-4-2-6-27(32)19-23-41(34)36)29-17-21-40(22-18-29)20-16-26-10-14-31(15-11-26)44-25-30-13-12-28-7-3-5-9-33(28)39-30/h2-15,24H,16-23,25H2,1H3
• InChIKey: TULGGJGJQXESOO-UHFFFAOYSA-N
• SMILES: COC(=O)C1=CN=C2N1CCC3=CC=CC=C3C2=C4CCN(CC4)CCC5=CC=C(C=C5)OCC6=NC7=CC=CC=C7C=C6

Laniquidar（Cat No.:I007616）is a selective inhibitor of P-glycoprotein (P-gp), a membrane transport protein involved in the efflux of drugs from cells, particularly in the blood-brain barrier. By inhibiting P-gp, Laniquidar can increase the brain penetration of various drugs, making it a potential therapeutic strategy for enhancing the efficacy of central nervous system (CNS) drugs, including chemotherapy agents for brain tumors. It has been investigated in combination with other drugs to overcome multidrug resistance (MDR) in cancer treatment. Clinical studies are ongoing to assess its safety, efficacy, and potential applications in cancer and CNS disorders.